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Résumé en
anglais
Decitabine is a hydrophilic drug that acts by hypomethylating DNA and is used in
Europe for the treatment of acute myeloid leukemia (AML) in older patients.
However, it can only be administered intravenously, due to very low oral
bioavailability. Oral administration would allow outpatient treatment, improving
quality of life and reducing treatment costs. The aim of this study was to develop
and characterize lipid nanocapsules (LNCs), originally designed for lipophilic drugs
(1), to encapsulate decitabine.
According to a previous formulation developed by Vrignaud et al. (2), LNCs
associated with a mixture of Transcutol® HP and Tween® 80 (THP-T80-LNCs)
were designed. Size and drug payload (determined after an ultracentrifugation to
collect the free decitabine and the decitabine loaded in THP-T80-LNCs) were
determined. 
A size of 26.5 ± 0.5 nm, a high encapsulation efficiency (over 85%), and a drug
payload of 472 ± 64 µg/mL were obtained. Then, a plasma stability of free-
decitabine and decitabine-loaded THP-T80-LNCs was performed. After
encapsulation, decitabine degradation was slowed down in comparison to the free-
drug. Finally, decitabine-loaded THP-T80-LNC cytotoxicity was evaluated on two
AML cell lines depending on their decitabine resistance: HEL (not resistant) and
HL-60 (resistant). Moreover, in vitro permeability study of decitabine-loaded THP-
T80-LNCs was assessed in a Caco-2 cell model (3). Decitabine cytotoxicity against
HEL and HL-60 was higher when decitabine was loaded in THP-T80-LNCs than
when free. Apparent permeability on Caco-2 cell monolayers was also increased
after encapsulation.
To conclude, THP-T80-LNCs were able to encapsulate a hydrophilic drug,
decitabine. Cytotoxicity of the drug was enhanced on two AML cell lines, as well as
its apparent permeability on Caco-2 cell monolayers suggesting a potentially useful
formulation to increase the oral bioavailability of decitabine.
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